Prestige Consumer Healthcare INC 8-K filings

Prestige Consumer Healthcare Inc. announced the retirement of Senior Vice President, Operations, Jeffrey Zerillo, effective August 14, 2026.

Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, exceeding revenue and earnings expectations, and raised its full-year financial outlook following the successful closure of two key acquisitions.

Prestige Consumer Healthcare Inc. announced the issuance of $400 million in 6.250% senior notes due 2034 through its subsidiary, Prestige Brands, Inc.

Prestige Consumer Healthcare Inc. files an amended 8-K to clarify financial statements related to its acquisition of the Breathe Right and other brands from Foundation Consumer Brands, LLC.

Prestige Consumer Healthcare Inc. has closed its acquisition of LaCorium Health, priced a $400 million senior notes offering, and will report Q1 FY2027 earnings on August 6, 2026.

Prestige Consumer Healthcare Inc. files an 8-K/A to provide financial statements and pro forma information related to its acquisition of the OTC Wellness Business from Foundation Consumer Brands, LLC.

Prestige Consumer Healthcare Inc. has finalized its $1.045 billion acquisition of the Breathe Right brand and other assets, financed through new term loan facilities and an amended revolving credit agreement.

Prestige Consumer Healthcare announced fiscal year 2026 results, reporting $1,088.7 million in revenue and $4.38 in adjusted diluted EPS, alongside the agreement to acquire Australian therapeutic skincare company LaCorium Health for approximately $150 million.

Prestige Consumer Healthcare Inc. announced the acquisition of Breathe Right and other OTC brands for $1.045 billion, expanding its consumer health portfolio.

Prestige Consumer Healthcare Inc. reported Q3 FY26 revenue of $283.4 million, exceeding outlook, but saw overall revenue and EPS declines driven by Clear Eyes supply constraints.

Prestige Consumer Healthcare Inc. reported Q2 FY26 results surpassing sales and earnings forecasts, driven by supply timing and retailer orders, and updated its full-year adjusted EPS outlook to the high end of its previous range.

Prestige Consumer Healthcare Inc. reported a revenue decline in Q1 FY26 due to eye care supply constraints but announced the strategic acquisition of Pillar5 Pharma Inc. to secure long-term supply, while revising its full-year outlook downward.

Prestige Consumer Healthcare Inc. announced record fiscal 2025 revenue of $1,137.8 million and diluted EPS of $4.29, with adjusted diluted EPS growing 7.4% year-over-year.

Prestige Consumer Healthcare Inc. announced record third-quarter results with revenue up 2.7% and raised its full-year earnings outlook, driven by strong international performance and improved Clear Eyes revenues.

Prestige Consumer Healthcare has expanded CFO Christine Sacco's role to include Chief Operating Officer responsibilities, effective immediately.

Prestige Consumer Healthcare reported second quarter results that surpassed expectations, driven by international growth and disciplined capital allocation, while reaffirming its full-year fiscal 2025 outlook.

Prestige Consumer Healthcare reported first quarter fiscal 2025 results with revenue of $267.1 million, exceeding expectations, and reaffirmed its full-year outlook.

Prestige Consumer Healthcare reported its fiscal year 2024 results, which included a slight revenue decrease and a new $300 million share repurchase program, while also facing supply chain challenges.

Prestige Consumer Healthcare has announced the appointment of John F. Kelly, a former Pfizer executive, to its Board of Directors, effective May 7, 2024.

Prestige Consumer Healthcare reported strong third-quarter results, exceeding revenue and earnings expectations, and raised its full-year earnings outlook.